Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2017-01-26

FDA Approved: TOVIAZ — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)

View source ↗

Summary

The FDA approved a supplemental application for TOVIAZ (fesoterodine fumarate) submitted by Pfizer Laboratories Div Pfizer Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Toviaz (fesoterodine fumarate)

Snippet

SUPPL AP for TOVIAZ (FESOTERODINE FUMARATE)